Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo

Drug Metabolism and Disposition

Volumn 40, Issue 1, 2012, Pages 54-63

  Raccor, Brianne S ^a,c   Claessens, Adam J ^a   Dinh, Jean C ^a   Park, Julie R ^b,c,d   Hawkins, Douglas S ^b,c,d   Thomas, Sushma S ^c   Makar, Karen W ^c   McCune, Jeannine S ^a,c   Totah, Rheem A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYLIDENE 1,5 DIMETHYL 3,3 DIPHENYLPYRROLIDINE; 4 HYDROXYCYCLOPHOSPHAMIDE; ALPHA HYDROXYMIDAZOLAM; CLOPIDOGREL; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOCHROME P450 2B6; DACTINOMYCIN; DOXORUBICIN; KETOCONAZOLE; MERCAPTOPURINE; MONTELUKAST; N 3 BENZYLNIRVANOL; NORMEPHENYTOIN; RADAFAXINE; SULFAPHENAZOLE; TIOGUANINE; TOPOTECAN; TROLEANDOMYCIN; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CHILD; COMPETITIVE INHIBITION; CYTOCHROME P450 2B6 GENE; CYTOCHROME P450 3A4 GENE; CYTOCHROME P450 3A5 GENE; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; EWING SARCOMA; FEMALE; GENE; GENOTYPE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; NEUROBLASTOMA; PHARMACOGENETICS; PRESCHOOL CHILD; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ARYL HYDROCARBON HYDROXYLASES; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; GENETIC VARIATION; HUMANS; INFANT; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING;

EID: 84455171516     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.039347     Document Type: Article

References (39)

1. Chang TK, Weber GF, Crespi CL, and Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450-2b and P450-3a in human liver microsomes. Cancer Res 53:5629-5637. (Pubitemid 23360263)
2. Cheesman MJ, Baer BR, Zheng YM, Gillam EM, and Rettie AE (2003) Rabbit CYP4B1 engineered for high-level expression in Escherichia coli: ligand stabilization and processing of the N-terminus and heme prosthetic group. Arch Biochem Biophys 416:17-24. (Pubitemid 36818845)
3. de Jonge ME, Huitema AD, Rodenhuis S, and Beijnen JH (2005a) Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 44:1135-1164. (Pubitemid 41483700)
4. de Jonge ME, Huitema AD, van Dam SM, Rodenhuis S, and Beijnen JH (2005b) Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes. Anticancer Drugs 16:331-336. (Pubitemid 40283949)
5. Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, and Huitema AD (2008) Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics 18:515-523. (Pubitemid 351769919)
6. Griskevicius L, Yasar U, Sandberg M, Hidestrand M, Eliasson E, Tybring G, Hassan M, and Dahl ML (2003) Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. Eur J Clin Pharmacol 59:103-109. (Pubitemid 36793721)
7. Helsby N and Tingle M (2011) The importance of correct assignment of CYP2B6 genetic variants with respect to cyclophosphamide metabolizer status. Am J Hematol 86:383-384.
8. Helsby NA, Hui CY, Goldthorpe MA, Coller JK, Soh MC, Gow PJ, De Zoysa JZ, and Tingle MD (2010) The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. Br J Clin Pharmacol 70:844-853.
9. Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, Greenblatt DJ, and Court MH (2004) Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14:225-238. (Pubitemid 38530514)
10. Huang W, Lin YS, McConn DJ 2nd, Calamia JC, Totah RA, Isoherranen N, Glodowski M, and Thummel KE (2004) Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 32:1434-1445. (Pubitemid 39564564)
11. Huang Z, Roy P, and Waxman DJ (2000) Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 59:961-972. (Pubitemid 30110812)
12. Jacob RM, Johnstone EC, Neville MJ, and Walton RT (2004) Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping. Clin Chem 50:1372-1377. (Pubitemid 38970644)
13. Kumar V, Rock DA, Warren CJ, Tracy TS, and Wahlstrom JL (2006) Enzyme source effects on CYP2C9 kinetics and inhibition. Drug Metab Dispos 34:1903-1908. (Pubitemid 44771720)
14. Lang T, Klein K, Fischer J, Nüssler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, and Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415. (Pubitemid 32656581)
15. Lasker JM, Wester MR, Aramsombatdee E, and Raucy JL (1998) Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys 353:16-28. (Pubitemid 28373025)
16. Lee CA, Neul D, Clouser-Roche A, Dalvie D, Wester MR, Jiang Y, Jones JP 3rd, Freiwald S, Zientek M, and Totah RA (2010) Identification of novel substrates for human cytochrome P450 2J2. Drug Metab Dispos 38:347-356.
17. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162-172. (Pubitemid 34680528)
18. McCune JS, Risler LJ, Phillips BR, Thummel KE, Blough D, and Shen DD (2005) Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab Dispos 33:1074-1081. (Pubitemid 41002791)
19. McCune JS, Salinger DH, Vicini P, Oglesby C, Blough DK, and Park JR (2009) Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group. J Clin Pharmacol 49:88-102.
20. Mitsuda M and Iwasaki M (2006) Improvement in the expression of CYP2B6 by co-expression with molecular chaperones GroES/EL in Escherichia coli. Protein Expr Purif 46:401-405.
21. Nakajima M, Komagata S, Fujiki Y, Kanada Y, Ebi H, Itoh K, Mukai H, Yokoi T, and Minami H (2007) Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics 17:431-445. (Pubitemid 46763388)
22. Naraharisetti SB, Lin YS, Rieder MJ, Marciante KD, Psaty BM, Thummel KE, and Totah RA (2010) Human liver expression of CYP2C8: gender, age, and genotype effects. Drug Metab Dispos 38:889-893.
23. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
24. Pinto N, Ludeman SM, and Dolan ME (2009) Drug focus: pharmacogenetic studies related to cyclophosphamide-based therapy. Pharmacogenomics 10:1897-1903.
25. Qiu R, Kalhorn TF, and Slattery JT (2004) ABCC2-mediated biliary transport of 4-glutathionylcyclophosphamide and its contribution to elimination of 4-hydroxycyclophosphamide in rat. J Pharmacol Exp Ther 308:1204-1212. (Pubitemid 38263999)
26. Ren S, Yang JS, Kalhorn TF, and Slattery JT (1997) Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 57:4229-4235. (Pubitemid 27413430)
27. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
28. Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, Décosterd L, Blievernicht J, Saussele T, Günthard HF, Schwab M, et al. (2007) Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 81:557-566. (Pubitemid 46454205)
29. Roy P, Yu LJ, Crespi CL, and Waxman DJ (1999) Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 27:655-666. (Pubitemid 29252439)
30. Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, and Spector SA (2007) CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 21:2191-2199. (Pubitemid 350287217)
31. Scott EE, Spatzenegger M, and Halpert JR (2001) A truncation of 2B subfamily cytochromes P450 yields increased expression levels, increased solubility, and decreased aggregation while retaining function. Arch Biochem Biophys 395:57-68. (Pubitemid 33030143)
32. Talakad JC,Kumar S, and Halpert JR (2009) Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs. Drug Metab Dispos 37:644-650.
33. Tian Q, Zhang J, Tan TM, Chan E, Duan W, Chan SY, Boelsterli UA, Ho PC, Yang H, Bian JS, et al. (2005) Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm Res 22:1837-1853. (Pubitemid 41504337)
34. Timm R, Kaiser R, Lötsch J, Heider U, Sezer O, Weisz K, Montemurro M, Roots I, and Cascorbi I (2005) Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 C19. Pharmacogenomics J 5:365-373.
35. Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, and Kharasch ED (2008) Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 108:363-374. (Pubitemid 351304229)
36. Vuppugalla R, Chang SY, Zhang H, Marathe PH, and Rodrigues DA (2007) Effect of commonly used organic solvents on the kinetics of cytochrome P450 2B6- and 2C8-dependent activity in human liver microsomes. Drug Metab Dispos 35:1990-1995. (Pubitemid 350005206)
37. Walsky RL, Obach RS, Gaman EA, Gleeson JP, and Proctor WR (2005) Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab Dispos 33:413-418. (Pubitemid 40279942)
38. Xie H, Griskevicius L, Ståhle L, Hassan Z, Yasar U, Rane A, Broberg U, Kimby E, and Hassan M (2006) Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur J Pharm Sci 27:54-61. (Pubitemid 41728255)
39. Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, and Rane A (2003) Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 3:53-61. (Pubitemid 36432466)